Merck-Ridgeback COVID drug cut hospitalizations, deaths by 50%
Molnupiravir, an investigational oral medicine against COVID-19 developed by Merck & Co. Inc. and Ridgeback Biotherapeutics, “reduced the risk of hospitalization or death by approximately 50%…